HOBAN DJ, BELLYOU T, PALATNICK L, NICHOL K, ZHANEL GG; Interscience Conference on Antimicrobial Agents and Chemotherapy (42nd : 2002 : San Diego, Calif.).

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2002 Sep 27-30; 42: abstract no. E-1140.

Health Sciences Centre and University of Manitoba, Winnipeg, MB, Canada

BACKGROUND: The emergence of penicillin, macrolide, fluoroquinolone and multi-drug resistant SPN worldwide has accelerated the development of new antimicrobials. Tigecycline (TGC) is a new semi-synthetic glycylcycline that exhibits activity against many gram positive/negative pathogens. In this study the activity of TGC, doxycycline (DOX), clarithromycin (CLAR), amoxicillin (AMOX), TMP-SMX (T/S) and levofloxacin (LEV) was determined against 865 SPN, including isolates with resistant (R) phenotypes. METHODS: Between November 1/2001 and April 1/2002, 850 clinically significant SPN were collected from 25 hospitals across Canada. MICs to TGC and comparative agents were determined following NCCLS guidelines. RESULTS: MIC[90]s of all isolates and resistant phenotypes are shown below: Conclusion: The new glycylcycline Tigecycline exhibits potent activity against SPN, including isolates with resistant phenotypes. TGC MICs were Publication Types:

• Meeting Abstracts

Keywords:

• Anti-Bacterial Agents
• CL 331002
• Canada
• Doxycycline
• Fluoroquinolones
• In Vitro
• Microbial Sensitivity Tests
• Minocycline
• Penicillins
• Streptococcus pneumoniae
• Tetracyclines
• tigecycline

Other ID:

• GWAIDS0028694

UI: 102268318

From Meeting Abstracts